Cure for certain cancers is ‘realistic’ goal in next decade, pharma lead says

Live updates

1. 1h ago

   Pharma Lead Sees Certain Cancer Cures as Realistic Goal Within Decade

   Johnson & Johnson CEO Joaquin Duato expects cures for some cancers within 10 years. This projection follows advancements in immunotherapy and multiple myeloma treatments. New therapeutic options now include CAR-T therapies and bispecific antibodies.

   What's confirmed:

   • CAR-T therapies and bispecific antibodies are expanding treatment options for resistant solid tumors.
   • Moderna and Merck are testing a personalized mRNA vaccine with KEYTRUDA.

   Still unconfirmed:

   • These therapies carry potential risks including cytokine release syndrome.
   confidence 80%
2. 5d ago

   Johnson & Johnson CEO views cancer cure as realistic goal for next decade

   Johnson & Johnson Chairman and CEO Joaquin Duato believes curing certain cancers is a realistic goal within 10 years. This outlook follows progress in immunotherapy and multiple myeloma treatments. A partnership between Moderna and Merck is currently testing a personalized mRNA vaccine with KEYTRUDA.

   What's confirmed:

   • Johnson & Johnson Chairman and CEO Joaquin Duato stated a cure for certain cancers is a realistic goal in the next decade.
   • Merck and Moderna are testing a personalized mRNA vaccine combined with KEYTRUDA.
   confidence 100%
3. 8d ago

   Pharma Lead Views Certain Cancer Cures as Realistic Within Ten Years

   Johnson & Johnson CEO Joaquin Duato expects some cancers to be curable in the next decade. He cites advancements in immunotherapy and multiple myeloma treatments. A collaboration between Merck and Moderna is testing a personalized mRNA vaccine combined with KEYTRUDA.

   What's confirmed:

   • Johnson & Johnson CEO Joaquin Duato believes curing some cancers is a realistic goal for the next decade.
   • A personalized mRNA vaccine paired with the drug KEYTRUDA is showing promising results for melanoma patients.
   • The Merck and Moderna collaboration developed an injectable treatment that reduces cancer recurrence over a five-year period.
   confidence 100%
4. 12d ago

   J&J CEO views certain cancer cures as realistic within 10 years

   Johnson & Johnson CEO Joaquin Duato believes curing some cancers is a realistic goal for the next decade. He points to immunotherapy breakthroughs and progress in multiple myeloma. New data shows a specific treatment is reducing death risks for myeloma patients.

   What's confirmed:

   • Johnson & Johnson CEO Joaquin Duato stated that curing certain cancers is a realistic goal in the next decade.
   • Duato cited immunotherapy and multiple myeloma progress as drivers for this goal.
   • Some multiple myeloma patients have been in remission for over five years due to immunotherapy breakthroughs.

   Still unconfirmed:

   • Phase 3 MonumenTAL-3 data showed TALVEY cuts myeloma death risk 53%.
   • Johnson & Johnson has a $1B bet on a preclinical KRAS protein degrader.
   confidence 90%
5. 13d ago

   J&J CEO Calls Cure for Certain Cancers a Realistic Goal Within Decade

   Johnson & Johnson CEO Joaquin Duato states that curing certain cancers in the next 10 years is a realistic goal. He cited progress in immunotherapy and multiple myeloma as key drivers. The company is prioritizing oncology and neuroscience over the obesity drug market.

   What's confirmed:

   • Johnson & Johnson CEO Joaquin Duato believes curing certain cancers within a decade is a realistic goal.
   • The company is avoiding the GLP-1 obesity medication space to focus on cancer treatments.
   • Duato cited immunotherapy and multiple myeloma progress as evidence of significant advances.
   • Joaquin Duato spoke about these goals at a CEO summit in London.
   • AI is assisting Johnson & Johnson in developing medicines more quickly.

   Still unconfirmed:

   • Johnson & Johnson agreed to acquire Firefly Bio for $1 billion.
   • The company aims to be the number one provider of cancer treatments by 2030.
   confidence 95%